CollPlant Biotechnologies (CLGN) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CollPlant Biotechnologies is the larger company by market cap ($7.5 million vs $7.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLGN | SKYE |
|---|---|---|
| Share price | $3.97 | $1.68 |
| Market cap | $7.51M | $7.44M |
| 1-day change | +14.74% | +1.82% |
| EPS (TTM) | $-9.33 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.80 | $14.08 |
| 52-week low | $2.64 | $1.50 |
| Distance from 52-week high | -85.19% | -88.07% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +3947.62% |
| Average volume | 351.98K | 89.28K |
| Shares outstanding | 1.89M | 4.43M |
| Employees | 39 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CollPlant Biotechnologies
CLGN stock →CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Healthcare · Biotechnology · 39 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
CLGN vs SKYE FAQ
Which is bigger, CollPlant Biotechnologies or Skye Bioscience?
CollPlant Biotechnologies (CLGN) is larger, with a market capitalization of $7.51M compared with $7.44M for Skye Bioscience (SKYE).
Are CollPlant Biotechnologies and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.